Adaptimmune Therapeutics PLC: Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel -- Overall response rate

Related Keywords

Pennsylvania ,United States ,Philadelphia ,Vancouver ,British Columbia ,Canada ,America ,Briana Van ,Julip Miller ,Dana Lynch ,Sarcoma Foundation Of America ,Washington University School Of Medicine ,Nasdaq ,Exchange Commission ,Corporate Communications ,Connective Tissue Oncology Society ,United Newsfile Corp ,Corporate Affairs ,Washington University School ,Elliot Norry ,Chief Medical Officer ,Hope Award ,Sarcoma Foundation ,Specific Peptide Enhanced Affinity Receptor ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Senior Director ,Adaptimmune ,Herapeutics ,Data ,Rom ,Cohort ,Spearhead ,Trial ,Photos ,Ontinue ,Support ,Submission ,Yfami ,Synovial ,Tarcoma ,Response ,Gate ,Durability ,Emain ,Consistent ,